| PEDIATRIC BIOSCIENCE LICENSES TECHNOLOGIES FROM UNIVERSITY OF CALIFORNIA, DAVIS, TO BRING TO MARKET EARLY DIAGNOSTICS FOR AUTISM
Announces Hiring of Dr. Thomas R. Anderson as CEO
SACRAMENTO, California (July 27, 2006) — Pediatric Bioscience LLC, today announced the hiring of Dr. Thomas R. Anderson as the founding CEO and the licensing of three technologies from the University of California, Davis. Pediatric Bioscience was formed by a group of researchers, parents and experienced business leaders with the goal of bringing to market diagnostics and therapeutics to diagnose and eventually treat children with autism.
"Great advances in medicine are brought to market by a combination of public research and private enterprise," said Dr. Anderson, CEO of Pediatric Bioscience. "By building on the work done by the research team at the UC Davis M.I.N.D. Institute, we can have a direct positive impact on children with autism and their families by bringing to market reliable diagnostic tests for autism."
Pediatric Bioscience has licensed three promising discoveries of the UC Davis M.I.N.D. Institute, a multidisciplinary research center striving to find causes, improved treatments and ultimately cures for neurodevelopmental disorders. The licensed technologies include
1. A prenatal assessment of increased risk of delivering a
child with autism by detecting certain auto-antibodies in
the blood of the prospective mothers, and
2. A method for detecting autism biochemically, rather than
by observed behavior, allowing for much earlier identification
of children with autism "The M.I.N.D. Institute was founded on the promise to parents to take the quickest path possible to finding answers to autism," said Dr. Robert Hendren, executive director of the UC Davis M.I.N.D. Institute. "We are coming closer every day to fulfilling that promise with new discoveries on the biological markers of autism. We're thrilled that our research outcomes will be developed further and will eventually be available to the broader community of scientists and clinicians."
Dr. Thomas R. Anderson is an experienced executive with successful tenures at several early stage bio-pharmaceutical companies. He founded Berkeley Antibody Company (BAbCO) and was instrumental in the growth of the company through its successful sale to Covance. He most recently served as the CEO of Lipomics Technologies of West Sacramento, California, a leading metabolomics company with capabilities in quantifying lipid metabolites and interpreting their biological significance.
Dr. Anderson received his Ph.D. from the University of California, Berkeley. He was a post-doctoral fellow in molecular biology and endocrinology at the University of California, San Francisco. About Pediatric Bioscience
Pediatric Bioscience LLC was formed in 2006 by a group of researchers, parents and experienced business leaders with the goal of bringing to market diagnostics and therapeutics to diagnose and eventually treat children with autism. The company is based in Sacramento, California.
About the UC Davis M.I.N.D. Institute
The UC Davis M.I.N.D. (Medical Investigation of Neurodevelopmental Disorders) is a unique, collaborative center bringing together parents, scientists, clinicians and educators for research on autism, fragile X syndrome, learning disabilities and other neurodevelopmental disorders. For more information, visit www.mindinstitute.org.
Media Contacts:
For information on Pediatric Bioscience
Josh Morgan
Morgan/Dorado Public Relations
Phone: (916) 941.0901
Email: josh@morgandorado.com
For information on technology transfer at UC Davis
Andy Fell
UC Davis News Service
Phone: (530) 752.4533
Email: ahfell@ucdavis.edu
For information on the UC Davis M.I.N.D. Institute
Karen Finney
UC Davis Health System News Service
Phone: (916) 734.9064
Email: karen.finney@ucdmc.ucdavis.edu |
